行情

XBIO

XBIO

Xenetic
NASDAQ

实时行情|Nasdaq Last Sale

1.440
-0.030
-2.04%
盘后: 1.390 -0.05 -3.47% 19:38 09/20 EDT
开盘
1.440
昨收
1.470
最高
1.500
最低
1.400
成交量
21.45万
成交额
--
52周最高
54.60
52周最低
1.350
市值
539.12万
市盈率(TTM)
-0.1160
分时
5日
1月
3月
1年
5年

EPS

XBIO 新闻

  • 周末要闻:美股终结三周连涨 埃及股市暴跌触发熔断
  • 新浪美股.2小时前
  • 外盘头条:特朗普再次呼吁美联储将利率降至零以下
  • 新浪美股.4小时前
  • 华为苹果正面交锋 同时发布新品谁主沉浮?
  • 证券日报.5小时前
  • 德国银行业协会预计该国GDP增长率为0.5%
  • 新浪美股.8小时前

更多

所属板块

生物技术和医学研究
+0.62%
制药与医学研究
+0.95%

热门股票

名称
价格
涨跌幅

XBIO 简况

Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on discovery, research and development of biologic drugs and novel oncology therapeutics. The Company’s lead investigational product candidate is oncology therapeutic XBIO-101, which is used for the treatment of progestin - resistant endometrial cancer. The Company is currently conducting a Phase 2 trial for XBIO-101. The Company’s lead proprietary technology is PolyXen, which enables platform technology that can be applied to protein or peptide therapeutics using the natural polymer polysialic acid. The Company’s technology includes XBIO-101, PolyXen, OncoHist, ErepoXen and ImuXen. ErepoXen or polysialylated erythropoietin is an internal drug candidate which uses the company’s PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients.
展开

Webull提供Xenetic Biosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。